Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by wildbird1on Aug 15, 2019 8:53am
178 Views
Post# 30030831

1,600 tests..

1,600 tests..Some members on this board are asking (with good reason) why the 1,600 tests number do not increase.
The 1,600 tests are mostly from small practices.

In the CC presentation Apr. 3, 2019 J.Tripp did say (QUOTE) ''So , it's not that you can't do it in the small practice space, but it is very expansive, very slow, very high resource. So we will stay in the small practice space, but as I said, we expect it to be only 10% of what we're doing.
The real breackout will be coming as we move into other areas.And that started with the telehealth initiative. It continue with the Midwest Hospital Group. It continue with the high risk employees''(End Of Quote).

To resume :
Don't expect the small practice tests number to increase, as J.Tripp is concentrating the big money on the bigger targets.


Bullboard Posts